Vani Vannappagari, PhD, MPH is Vice President & Global Head of Epidemiology and Real World Evidence at ViiV Healthcare. In this role she sets the strategy for conducting studies to collect real world evidence on treatment effectiveness, adherence and safety of the antiretroviral drugs. She also leads studies in pregnancy and registries that evaluate drug safety during pregnancy; and non-interventional studies in pediatric and adolescent populations. She is the industry co-chair of the Antiretroviral Pregnancy Registry steering committee.
Prior to joining ViiV Healthcare, she was director of infectious disease epidemiology at GlaxoSmithKline leading epidemiology projects for HIV, Influenza, Anthrax and Malaria drug development. Her work involved disease epidemiology, pharmacovigilance and post marketing drug safety, pregnancy and drug exposure registries. Dr. Vannappagari has MBBS from Karnatak Medical College, India and MPH & PhD in epidemiology from the University of North Carolina at Chapel Hill.
